[go: up one dir, main page]

ECSP10010576A - Formulaciones orales e inyectables de compuestos de tetraciclina - Google Patents

Formulaciones orales e inyectables de compuestos de tetraciclina

Info

Publication number
ECSP10010576A
ECSP10010576A EC2010010576A ECSP10010576A ECSP10010576A EC SP10010576 A ECSP10010576 A EC SP10010576A EC 2010010576 A EC2010010576 A EC 2010010576A EC SP10010576 A ECSP10010576 A EC SP10010576A EC SP10010576 A ECSP10010576 A EC SP10010576A
Authority
EC
Ecuador
Prior art keywords
oral
tetracicline
compounds
injectable formulations
minocycline
Prior art date
Application number
EC2010010576A
Other languages
English (en)
Inventor
Sean Johnston
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41114256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of ECSP10010576A publication Critical patent/ECSP10010576A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulacion oral de 9-[(2,2-dimetil propil amino)-metil]-minociclina o una sal de la misma en forma de tableta.
EC2010010576A 2008-03-28 2010-10-27 Formulaciones orales e inyectables de compuestos de tetraciclina ECSP10010576A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4039808P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
ECSP10010576A true ECSP10010576A (es) 2010-12-30

Family

ID=41114256

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010576A ECSP10010576A (es) 2008-03-28 2010-10-27 Formulaciones orales e inyectables de compuestos de tetraciclina

Country Status (30)

Country Link
US (2) US9314475B2 (es)
EP (3) EP3348258B1 (es)
JP (7) JP2011515473A (es)
KR (3) KR101893740B1 (es)
CN (1) CN102046177B (es)
AU (1) AU2009229174A1 (es)
BR (2) BRPI0909211B8 (es)
CA (2) CA2719751C (es)
CL (1) CL2010000281A1 (es)
CO (1) CO6300935A2 (es)
CY (2) CY1120240T1 (es)
DK (2) DK2271348T3 (es)
EC (1) ECSP10010576A (es)
ES (2) ES2836448T3 (es)
HR (2) HRP20180836T1 (es)
HU (2) HUE052201T2 (es)
IL (1) IL208440A0 (es)
LT (2) LT2271348T (es)
MA (1) MA32275B1 (es)
MX (1) MX2010010585A (es)
NO (1) NO2271348T3 (es)
NZ (1) NZ588428A (es)
PL (2) PL2271348T3 (es)
PT (2) PT2271348T (es)
RU (1) RU2010144130A (es)
SI (2) SI3348258T1 (es)
TR (1) TR201806893T4 (es)
UA (2) UA122762C2 (es)
WO (1) WO2009120389A1 (es)
ZA (1) ZA201007013B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2717703A1 (en) 2008-03-05 2009-09-11 Paratek Pharmaceuticals, Inc. Minocycline compounds and methods of use thereof
TW202332671A (zh) * 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
BR112012028524B1 (pt) 2010-05-12 2022-03-15 Rempex Pharmaceuticals, Inc Composições farmacêuticas e respectivos usos, métodos de preparação e kit
AU2017259960A1 (en) * 2016-05-02 2018-12-06 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (UTI) treatment
US10166912B2 (en) 2016-08-19 2019-01-01 Sl Corporation Automotive LED driving apparatus
SG10201913599RA (en) 2016-11-01 2020-02-27 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
CA3111447A1 (en) * 2018-09-04 2020-03-12 Paratek Pharmaceuticals, Inc. Methods of treating mycobacterial infections using tetracycline compounds
KR20220123057A (ko) * 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699054A (en) * 1953-10-09 1955-01-11 Lloyd H Conover Tetracycline
US2712517A (en) * 1954-03-03 1955-07-05 Bristol Lab Inc Production of tetracycline and substituted tetracyclines
US3019173A (en) * 1956-06-04 1962-01-30 American Cyanamid Co Method for preparing tetracycline
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US3005023A (en) * 1957-04-05 1961-10-17 American Cyanamid Co Production of tetracycline
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US2886595A (en) * 1958-09-30 1959-05-12 Bristol Lab Inc Tetracycline recovery
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3019260A (en) * 1959-05-13 1962-01-30 American Cyanamid Co Process for the catalytic reduction of 6-hydroxy hydronaphthacenes
FR1430859A (es) * 1960-05-23 1966-05-25
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3301899A (en) * 1963-11-27 1967-01-31 Bristol Myers Co Purification of tetracycline
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (es) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
DE69232302T4 (de) 1991-10-04 2003-02-13 American Cyanamid Co., Wayne 7-Substituierte-9-substituierte Amino-6-Demethyl-6-Deoxy-Tetracycline
US5494903A (en) * 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US6465431B1 (en) * 1999-11-17 2002-10-15 Boston Life Sciences, Inc. Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
CN1268888A (zh) 1997-08-29 2000-10-04 Dsm公司 不含赋形剂的颗粒
KR100252699B1 (ko) * 1998-03-17 2000-12-01 강재헌 치주염 치료용 미노사이클린 조성물
KR100701635B1 (ko) 1998-11-18 2007-03-30 콜라제넥스 파마슈티칼스, 인크 신규한 4-데디메틸아미노테트라시클린 유도체
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
EP1254666A4 (en) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS
BRPI0112269B8 (pt) * 2000-07-07 2021-05-25 Paratek Pharm Innc composto de minociclina 9-aminometila substituída, e, composição farmacêutica
IL157860A0 (en) 2001-03-13 2004-03-28 Paratek Pharm Innc 7,9-substituted tetracycline compounds
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US7045507B2 (en) * 2001-03-14 2006-05-16 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
WO2002083106A1 (en) * 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP2301915A1 (en) * 2001-07-13 2011-03-30 Paratek Pharmaceuticals, Inc. 7-(diethylamino)methyl substituted tetracycline having target therapeutic activities
IL163931A0 (en) 2002-03-08 2005-12-18 Paratek Pharm Innc Amino-methyl substituted tetracyline compounds
CN1390550A (zh) * 2002-07-25 2003-01-15 于航 盐酸米诺环素冻干粉针剂及其制备方法
EP1556007A4 (en) * 2002-10-24 2008-12-17 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
US8173624B2 (en) * 2002-10-24 2012-05-08 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate RNA
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
KR20050105451A (ko) * 2003-02-03 2005-11-04 네오팜 인코포레이티드 안정한 멸균 여과가능한 리포좀 캡슐화 탁산 및 다른항종양제
WO2004078111A2 (en) * 2003-03-06 2004-09-16 Ranbaxy Laboratories Limited Extended release minocycline compositions and processes for their preparation
WO2004091513A2 (en) * 2003-04-10 2004-10-28 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
KR101228706B1 (ko) * 2003-07-09 2013-02-01 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
WO2005009944A1 (en) * 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
US7786099B2 (en) * 2004-01-15 2010-08-31 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
GB2414668B (en) * 2004-06-03 2009-07-29 Dexcel Ltd Tetracycline modified release delivery system
RU2428190C2 (ru) 2005-03-14 2011-09-10 Вайет Составы на основе тигециклина и способы их получения
WO2007087416A2 (en) * 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
CA2717703A1 (en) * 2008-03-05 2009-09-11 Paratek Pharmaceuticals, Inc. Minocycline compounds and methods of use thereof

Also Published As

Publication number Publication date
ES2674708T3 (es) 2018-07-03
KR20160105532A (ko) 2016-09-06
KR20110008057A (ko) 2011-01-25
CN102046177B (zh) 2012-12-19
CY1123382T1 (el) 2021-12-31
MA32275B1 (fr) 2011-05-02
EP2271348B1 (en) 2018-03-28
NO2271348T3 (es) 2018-08-25
CL2010000281A1 (es) 2012-03-30
PT3348258T (pt) 2020-11-25
JP2019196408A (ja) 2019-11-14
HUE038257T2 (hu) 2018-10-29
EP3789030A1 (en) 2021-03-10
ZA201007013B (en) 2013-11-27
MX2010010585A (es) 2010-11-09
JP2018203778A (ja) 2018-12-27
LT3348258T (lt) 2020-12-10
PT2271348T (pt) 2018-04-16
UA122762C2 (uk) 2021-01-06
CA2984301A1 (en) 2009-10-01
BRPI0909211B1 (pt) 2020-08-25
KR101835574B1 (ko) 2018-03-08
BRPI0909211A2 (pt) 2016-11-29
DK2271348T3 (en) 2018-06-14
LT2271348T (lt) 2018-06-25
TR201806893T4 (tr) 2018-06-21
JP2011515473A (ja) 2011-05-19
PL2271348T3 (pl) 2018-08-31
WO2009120389A8 (en) 2009-12-30
KR101746228B1 (ko) 2017-06-12
KR101893740B1 (ko) 2018-08-30
RU2010144130A (ru) 2012-05-10
BR122020011180B1 (pt) 2021-03-23
DK3348258T3 (da) 2020-12-07
EP2271348A1 (en) 2011-01-12
SI3348258T1 (sl) 2020-12-31
US20160279151A1 (en) 2016-09-29
EP3348258A1 (en) 2018-07-18
WO2009120389A1 (en) 2009-10-01
IL208440A0 (en) 2010-12-30
HUE052201T2 (hu) 2021-04-28
KR20180026799A (ko) 2018-03-13
CA2984301C (en) 2020-10-27
CA2719751C (en) 2018-01-02
JP2023144043A (ja) 2023-10-06
EP3348258B1 (en) 2020-09-09
US9314475B2 (en) 2016-04-19
HK1257928A1 (en) 2019-11-01
JP6412521B2 (ja) 2018-10-24
EP2271348A4 (en) 2011-05-25
CA2719751A1 (en) 2009-10-01
CO6300935A2 (es) 2011-07-21
HRP20201883T1 (hr) 2021-01-22
ES2836448T3 (es) 2021-06-25
US20100056638A1 (en) 2010-03-04
JP5940119B2 (ja) 2016-06-29
JP2021167355A (ja) 2021-10-21
NZ588428A (en) 2012-08-31
PL3348258T3 (pl) 2021-03-08
HRP20180836T1 (hr) 2018-07-27
CY1120240T1 (el) 2019-07-10
CN102046177A (zh) 2011-05-04
SI2271348T1 (en) 2018-08-31
BRPI0909211B8 (pt) 2021-05-25
AU2009229174A1 (en) 2009-10-01
JP2014221820A (ja) 2014-11-27
BR122020011180B8 (pt) 2021-07-27
JP6577645B2 (ja) 2019-09-18
JP2016145260A (ja) 2016-08-12
UA109627C2 (uk) 2015-09-25

Similar Documents

Publication Publication Date Title
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
LTPA2018014I1 (lt) Farmacinė kompozicija 514
PA8774901A1 (es) Productos de cuidado oral y metodos para usar y fabricar el mismo
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
BRPI0811110A2 (pt) Formulação de nicotina oral tamponada com aminoácido
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BR112015014478A2 (pt) complexo de haleto de aminoácido e zinco com cisteína
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
NO20075628L (no) Farmasøytiske formuleringer
EP2068886A4 (en) LIPIDIC FORMULATIONS
DK1893184T3 (da) Oral doseringsform omfattende et antimisbrugssystem
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
NO20075111L (no) Farmasoytisk sammensetning
ES1063617Y (es) Cepillo dental
CL2012003012A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
RS54238B1 (en) ORAL FILM FORMULATIONS CONTAINING DAPOXETINE AND TADALAFIL
EA201170512A1 (ru) Композиция для перорального введения
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
CO6410282A2 (es) Formulaciones orales sólidas de una pirido-pirimidinona
SV2009003287A (es) Agentes para combatir parasitos en animales